VivoSeq
Hematology

Waldenstrom Macroglobulinemia

42

Pipeline Programs↗

1

Active Trials↗

22

Companies Involved↗

Waldenstrom macroglobulinemia is a moderately active landscape with 42 programs across 22 companies. The most active players are Calithera Biosciences, Inc, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb. 9 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

50/100

Attrition Rate

46/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Calithera Biosciences, Inc

1 program

Phase 1B

Beijing InnoCare Pharma Tech Co., Ltd.

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Gilead logo

Gilead

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

35 of 42 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody614%RNA therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Terminated5 · 38%
Withdrawn1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00923507·1,000 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Completed·MMayo Clinic·Phase 2·NCT00711828·21 enrolled
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
Completed·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT04440059·47 enrolled
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Completed·Takeda logoTakeda·Phase 1·NCT01118689·39 enrolled
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02371148·38 enrolled
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT01381692·9 enrolled
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
Completed·UUniversity Hospital, Lille·Phase 1/2·NCT02302469·17 enrolled
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Terminated·UUniversity of Washington·Phase 2·NCT03269552·4 enrolled
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Terminated·RRoswell Park Cancer Institute·Phase 2·NCT01536067·3 enrolled
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01779167·4 enrolled
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01198067·15 enrolled
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Terminated·MMayo Clinic·Phase 2·NCT03506373·21 enrolled
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Withdrawn·SWOG Cancer Research Network·Phase 2·NCT00723658

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)